Febuxostat Tablets 1

フェブキソスタット錠 2

3

4 Febuxostat Tablets contain not less than 95.0% and 5 not more than 105.0% of the labeled amount of febuxostat (C₁₆H₁₆N₂O₃S: 316.37). 6

7 Method of preparation Prepare as directed under Tablets, 8 with Febuxostat.

9 **Identification** Perform the test with 20 μ L each of the sample solution and standard solution obtained in the Assay as 10 directed under Liquid Chromatography <2.01>, according to 11 12 the following conditions: the retention times of the principal 13 peaks in the chromatograms obtained from the sample solu-14 tion and standard solution are the same, and both absorption 15 spectra of these peaks exhibit similar intensities of absorption 16 at the same wavelengths.

17 Operating conditions—

18 Column, column temperature, mobile phase, and flow rate: 19

Proceed as directed in the operating conditions in the Assay. 20 Detector: A photodiode array detector (wavelength: 317

21 nm, spectrum range of measurement: 210 - 350 nm).

22 System suitability—

23 System performance: Proceed as directed in the system suitability in the Assay. 24

25 Purity Related substances-To 5 tablets of Febuxostat 26 Tablets add 3V/4 mL of a mixture of acetonitrile and water 27 (3:2), shake vigorously for 30 minutes until the tablets com-28 pletely disintegrated, then add a mixture of acetonitrile and 29 water (3:2) to make exactly V mL so that each mL contains 30 about 1 mg of febuxostat (C16H16N2O3S). Centrifuge this so-31 lution, filter the supernatant liquid, and use the filtrate as the 32 sample solution. Pipet 1 mL of the sample solution, add a 33 mixture of acetonitrile and water (3:2) to make exactly 100 34 mL, and use this solution as the standard solution. Perform 35 the test with exactly 40 μ L each of the sample solution and stand-36 ard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak 37 38 area by the automatic integration method: The area of the 39 peaks other than the related substance TA, having the relative 40 retention time of about 0.4 to the related substance A ob-41 served in the solution for system suitability test, and febuxo-42 stat obtained from the sample solution are not larger than 1/5 43 times the peak area of febuxostat from the standard solution, 44 respectively. Furthermore, the total area of the peaks other 45 than febuxostat from the sample solution is not larger than 46 1/2 times the peak area of febuxostat from the standard solu-47 tion.

48 Operating conditions—

49 Detector: An ultraviolet absorption photometer (wave-50 length: 217 nm).

51 Column: A stainless steel column 4.6 mm in inside diam-

52 eter and 25 cm in length, packed with octadecylsilanized sil-

53 ica gel for liquid chromatography (5 μ m in particle diameter).

54 Column temperature: A constant temperature of about 55 40°C.

56 Mobile phase A: Diluted acetic acid (100) (1 in 5000).

57 Mobile phase B: A solution of acetic acid (100) in metha-58 nol (1 in 5000).

59 Flowing of mobile phase: Control the gradient by mixing 60 the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 - 40	$60 \rightarrow 0$	$40 \rightarrow 100$
40 - 60	0	100

Flow rate: 0.7 mL per minute.

61

62 Time span of measurement: For 60 minutes after injection. 63 System suitability—

64 Test for required detectability: Pipet 2mL of the standard 65 solution, and add a mixture of acetonitrile and water (3:2) to make exactly 10 mL. Confirm that the peak area of febuxostat 66 67 obtained with 40 μ L of this solution is equivalent to 14 to 68 26% of that with 40 μ L of the standard solution.

69 System performance: Dissolve 1 mg of Febuxostat Related 70 Substance A for System Suitability RS in a mixture of ace-71 tonitrile and water (3:2) to make 100 mL. To 1 mL of this 72 solution, add 10 mg of Febuxostat RS, add a mixture of ace-73 tonitrile and water (3:2) to make 10 mL, and use this solution 74 as the solution for system suitability test. When the procedure 75 is run with 40 μ L of the solution for system suitability test 76 under the above operating conditions, febuxostat and the related substance A are eluted in this order with the resolution 77 78 between these peaks being not less than 2.0.

79 System repeatability: When the test is repeated 6 times 80 with 40 μ L of the standard solution under the above operating 81 conditions, the relative standard deviation of the peak area of 82 febuxostat is not more than 2.0%.

83 Uniformity of dosage units <6.02> Perform the test ac-84 cording to the following method: it meets the requirement of 85 the Content uniformity test.

86 To 1 tablet of Febuxostat Tablets add 3V/4 mL of a mixture of acetonitrile and water (3:2), shake vigorously for 30 87 88 minutes until the tablets are completely disintegrated, then 89 add a mixture of acetonitrile and water (3:2) to make exactly 90 V mL. Centrifuge this solution, pipet a volume of the super-91 natant liquid, equivalent to about 4 mg of febuxostat 92 $(C_{16}H_{16}N_2O_3S)$, add a mixture of acetonitrile and water (3:2) 93 to make exactly 50 mL. Then pipet 2.5 mL of this solution, 94 add a mixture of acetonitrile and water (3:2) to make exactly 20 mL, filter this solution, and use the filtrate as the sample 95 96 solution. Then, proceed as directed in the Assay.

97 Amount (mg) of febuxostat (
$$C_{16}H_{16}N_2O_3S$$
)
98 $=M_S \times A_T / A_S \times C / 10$

- 99 M_S: Amount (mg) of Febuxostat RS taken
- 100 C: Labeled amount (mg) of febuxostat(C₁₆H₁₆N₂O₃S) in
- 101 1 tablet.

102 **Dissolution** <6.10> When the test is performed at 50 revo-103 lutions per minute according to the Paddle method, using 900 104 mL of disodium hydrogen phosphate-citric acid buffer solution (pH 5.5) as the dissolution medium for 10-mg and 20-105 mg tablets and 900 mL of 0.05 mol/L disodium hydrogen 106 156 phosphate-citric acid buffer solution (pH 6.0) as the dissolu-107 tion medium for a 40-mg tablet, the dissolution rates in 30 108 109 minutes of 10-mg and 40-mg tablets are not less than 80%, 110 and that in 60 minutes of a 20-mg tablet is not less than 75%. 111 Start the test with 1 tablet of Febuxostat Tablets, withdraw 112 not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter 113 114 with a pore size not exceeding 0.45 μ m. Discard not less than 115 10 mL of the first filtrate, pipet V mL of the subsequent filtrate, add 2nd fluid for disintegration test to make exactly V' 116 117 mL so that each mL contains about 11 μ g of febuxostat (C₁₆H₁₆N₂O₃S), and use this solution as the sample solution. 118 119 Separately, weigh accurately about 11 mg of Febuxostat RS, and dissolve in 2nd fluid for disintegration test to make ex-120 121 actly 50 mL. Pipet 5 mL of this solution, add 2nd fluid for 122 disintegration test to make exactly 100 mL, and use this so-123 lution as the standard solution. Determine the absorbances, A_T and A_S, of the sample solution and standard solution at 317 124 125 nm as directed under Ultraviolet-visible Spectrophotometry 126 <2.24>

127 Dissolution rate (%) with respect to the labeled amount of 128 febuxostat (C16H16N2O3S)

129
$$= M_{\rm S} \times A_{\rm T} / A_{\rm S} \times V' / V \times 1 / C \times 90$$

130 M_S: Amount (mg) of Febuxostat RS taken

131 C: Labeled amount (mg) of febuxostat(C₁₆H₁₆N₂O₃S)

in 1 tablet. 132

Assay To 10 tablets of Febuxostat Tablets add 3V/4 mL of 133 a mixture of acetonitrile and water (3:2), shake vigorously for 134 30 minutes until the tablets are completely disintegrated, then 135 add a mixture of acetonitrile and water (3:2) to make exactly 136 137 V mL. Centrifuge this solution, pipet a volume of the super-138 natant liquid, equivalent to about 4 mg of febuxostat 139 $(C_{16}H_{16}N_2O_3S)$, add a mixture of acetonitrile and water (3:2) 140 to make exactly 50 mL. Then pipet 2.5 mL of this solution, 141 add a mixture of acetonitrile and water (3:2) to make exactly 142 20 mL, filter this solution, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of Febux-143 ostat RS, dissolve in a mixture of a solution of acetonitrile 144 145 and water (3:2) to make exactly 200 mL. Pipet 5 mL of this 146 solution, add a mixture of acetonitrile and water (3:2) to make

147 exactly 25 mL, and use this solution as the standard solution. Perform the test with 20 μ L each of the sample solution and 148 149 standard solution as directed under Liquid chromatography 150 <2.01> according to the following conditions, and determine 151 the peak areas, $A_{\rm T}$ and $A_{\rm S}$, of febuxostat in each solution.

Amount (mg) of febuxostat (C₁₆H₁₆N₂O₃S)
=
$$M_{\rm S} \times A_{\rm T} / A_{\rm S} \times C / 10$$

M_S: Amount (mg) of Febuxostat RS taken

C: Labeled amount (mg) of febuxostat($C_{16}H_{16}N_2O_3S$) in 1 tablet.

Operating conditions—

152

153

154

155

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

185

Detector: An ultraviolet absorption photometer (wavelength: 317 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of a solution of acetic acid (100) in acetonitrile for liquid chromatography (1 in 500) and diluted acetic acid (100) (1 in 500) (3:2).

Flow rate: Adjust so that the retention time of febuxostat is about 6 minutes.

System suitability-

System performance: When the procedure is run with 20 μ L of the standard solution under the above operating conditions, the theoretical plates and the symmetry factor of the peak of febuxostat are not less than 1500 and 0.9 to 1.4, respectively.


System repeatability: When the test is repeated 6 times with 20 μ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of febuxostat is not more than 1.0%.

180 Containers and storage Containers—Tight containers.

181 Others

182 Related substance TA:

2-[3-Carbamoyl-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-183 thiazole-5-carboxylic acid 184



186 Add the following to 9.01 (1) Reference 187 Standards:

- 188 Febuxostat RS
- 189 Febuxostat Related Substance A for System Suitability RS